

INSTITUT MERIEUX IS BOLSTERING ITS MANAGEMENT TEAMS TO OVERCOME

NEW HEALTH CHALLENGES AROUND THE WORLD

Lyon, September 17, 2020 - Institut Mérieux, a family holding company dedicated to global public health, is bolstering its management team to take on the challenges of a particularly complex global health context, which faces growing needs and an acceleration in scientific and technological breakthroughs.

• On October 1, 2020, Philippe Sans will be named Executive Vice-President — Strategy and Planning at Institut Mérieux. He has served as CEO of Mérieux NutriSciences since 2007 and will remain on its Board of Directors.

Philippe Sans will offer Institut Mérieux his strategic vision, along with his deep familiarity with the group and the global health context.

Philippe Sans graduated from emlyon and has spent much of his career at Institut Mérieux. He held management positions at bioMérieux (in the field of diagnostics) in France and the United States for more than 20 years before joining Mérieux NutriSciences (food safety), where he has served as CEO since 2007. He turned this company into a global powerhouse in a field that was still emerging 13 years ago.

• On January 1, 2021, Philippe Archinard will join Institut Mérieux as Executive Vice-President — Technological Innovation and Scientific Partnerships. He was previously Chairman and CEO of Transgene, and will remain on its Board of Directors.

Philippe Archinard will provide Institut Mérieux with his scientific vision and expertise in technological innovation, which are critical in this particularly disruptive period.

Philippe Archinard has a chemical engineering degree, a PhD in biochemistry from the University of Lyon, and a PMD certificate from Harvard Business School. He started his career at bioMérieux, where he worked in R&D and operational management in France and the United States until 1999. He then served as CEO of Innogenetics in Belgium until 2004, when he joined Transgene as CEO, becoming Chairman and CEO in 2010. He is also Chairman of the Bioaster Institute for Technological Research.

Philippe Archinard and Philippe Sans will bolster Institut Mérieux's management team alongside Michel Baguenault, CEO.



• Nicolas Cartier will replace Philippe Sans as CEO of Mérieux NutriSciences on October 1.

Nicolas Cartier graduated from École Polytechnique, École Nationale des Ponts et Chaussées, and Institut d'Etudes Politiques de Paris. He started his career at Sanofi, holding business development, corporate, and operational responsibilities in France and abroad for more than 20 years. In 2013, he joined bioMérieux as Director of the Industrial Microbiology Global Business Unit. He then became Mérieux NutriSciences' COO in May 2020, contributing his expertise in the prevention of occupational health risks.

• Hedi Ben Brahim will replace Philippe Archinard as Chairman and CEO of Transgene in January 2021.

Hedi Ben Brahim graduated from Ecole Polytechnique and Ecole Nationale Supérieure des Mines de Paris. He started his career in the public sector at the Ministry of Economy, Action, and Public Accounts, then the Ministry of Social Affairs and Health. He then worked for the Vallourec group for 8 years, heading up sales, production, and strategy in France and the United States. In September 2018, he joined Institut Mérieux as Director of the Immunotherapy Department. He is Chairman of the Board of ABL Inc. and has been a member of the Transgene board since May 2019.

According to Alain Mérieux, Chairman of Institut Mérieux, "Institut Mérieux remains committed to its public health mission founded on a global, long-term vision. Our complementary strategic priorities in diagnostics, immunology, and food safety are more important than ever. The Institute's role as a holding company is to ensure the missions and work of our companies are consistent while respecting their governance. Institut Mérieux also establishes a global forward-looking strategy for our group in a context that has become particularly complex. For more than 20 years, Philippe Archinard and Philippe Sans have worked closely with me to build bioMérieux and develop the centers of expertise for Immunology and Food Safety. They bring to Institut Mérieux their expertise as well as their strategic and scientific vision. I have full confidence in their ability to take on the future challenges we face."

About Institut Mérieux

Institut Mérieux is a family holding company dedicated to global public health. Institut Mérieux takes a comprehensive approach to the fight against infectious diseases and cancers with five complementary companies: bioMérieux for *in vitro* diagnostics; Mérieux NutriSciences for food safety; Transgene for immunotherapy; ABL Inc. for contract research and bioproduction; and Mérieux Développement, a healthcare investment firm. Institut Mérieux has 20,000 employees all over the world and 3.2 billion euros in sales.



www.institut-merieux.com

Press Contacts : Image Sept

Claire Doligez – 01 53 70 74 48 – cdoligez@image7.fr

Laurence Heilbronn – 01 53 70 74 64 – Iheilbronn@image7.fr